ezaladcigene resoparvovec

Ezaladcigene resoparvovec is an investigational gene therapy designed to treat Parkinson's disease. It uses an adeno-associated virus serotype 2 (AAV2) vector to deliver the human aromatic L-amino acid decarboxylase (AADC) gene directly into the putamen region of the brain. The therapy aims to restore levels of the enzyme L-amino acid decarboxylase, which is critical for converting levodopa into dopamine—a neurotransmitter deficient in Parkinson’s disease. By increasing local dopamine production, it seeks to improve motor function and reduce symptoms in patients with advanced Parkinson’s disease[1][6]. The drug was developed by Voyager Therapeutics and Neurocrine Biosciences, with early work originating at University of California at San Francisco[1].

Other names

Aromatic-L-amino-acid-decarboxylase-gene-therapy